TITLE

Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010

AUTHOR(S)
Brinckmann, Sarah; da Costa, Kelly; van Gils, Marit J.; Hallengärd, David; Klein, Katja; Madeira, Luisa; Mainetti, Lara; Palma, Paolo; Raue, Katharina; Reinhart, David; Reudelsterz, Marc; Ruffin, Nicolas; Seifried, Janna; Schäfer, Katrein; Sheik-Khalil, Enas; Sköld, Annette; Uchtenhagen, Hannes; Vabret, Nicolas; Ziglio, Serena; Scarlatti, Gabriella
PUB. DATE
January 2011
SOURCE
Journal of Translational Medicine;2011, Vol. 9 Issue 1, p40
SOURCE TYPE
Academic Journal
DOC. TYPE
research
ABSTRACT
Novel, exciting intervention strategies to prevent infection with HIV have been tested in the past year, and the field is rapidly evolving. EUROPRISE is a network of excellence sponsored by the European Commission and concerned with a wide range of activities including integrated developmental research on HIV vaccines and microbicides from discovery to early clinical trials. A central and timely theme of the network is the development of the unique concept of co-usage of vaccines and microbicides. This review, prepared by the PhD students of the network captures much of the research ongoing between the partners. The network is in its 5th year and involves over 50 institutions from 13 European countries together with 3 industrial partners; GSK, Novartis and Sanofi-Pasteur. EUROPRISE is involved in 31 separate world-wide trials of Vaccines and Microbicides including 6 in African countries (Tanzania, Mozambique, South Africa, Kenya, Malawi, Rwanda), and is directly supporting clinical trials including MABGEL, a gp140-hsp70 conjugate trial and HIVIS, vaccine trials in Europe and Africa.
ACCESSION #
61043275

 

Related Articles

  • HIV vaccine failure prompts Merck to halt trial.  // Nature;9/27/2007, Vol. 449 Issue 7161, p390 

    The article reports on the failure of the human immunodeficiency virus (HIV) vaccine developed by Merck in the U.S. It is stated that the failure has caused Merck to halt its clinical trials. It reveals that the latest trial had begun in 2004 which enrolled 3,000 people considered to be at high...

  • Safety of Newer Parenteral Antibiotics. Stein, Gary E. // Clinical Infectious Diseases;9/1/2005 Supplement, Vol. 41, pS293 

    Several parenteral antimicrobials have been introduced into clinical practice over the course of the last decade. Some of these agents (e.g., linezolid, daptomycin, and tigecycline) are prototypes of new classes of compounds. In comparative clinical trials, these newer anti-infectives have been...

  • Innovotech receives green light for sale of bioFILM PA test.  // Edmontonians;Sep2009, Vol. 20 Issue 9, p20 

    The article focuses on the significance of the bioFILM PA test development to medical community in Edmonton, Alberta. It notes that the biofilm shows very positive results in choosing the appropriate antibiotic treatment for serious lung infections. Its clinical research reveals the test's...

  • Anidulafungin: A Viewpoint by José A. Vazquez. Vazquez, José A // Drugs;2004, Vol. 64 Issue 19, p2259 

    Presents the viewpoint of José A. Vazquez regarding the drug, anidulafungin. Description of the drug; Advantages of the drug over other antifungal medications; Benefits offered by the drug; Effectiveness of the drug in treating azole-refractory mucosal fungal infections in HIV-positive patients.

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Aug2007, Vol. 21 Issue 8, p602 

    The article offers news briefs on antiviral agents. Boehringer Ingelheim has started enrollment of its POTENT study. Gilead Sciences released their 144-week data from an ongoing clinical trial, Study 934, and comparing a once-daily regimen of Truvada. Abbott has received approval from 19 African...

  • Impact of pre-term antibiotics.  // Primary Health Care;Nov2008, Vol. 18 Issue 9, p6 

    The article presents a clinical trial on the impact of pre-term antibiotics among women with preterm rupture of membranes (PROM) in Great Britain. Experiment shows that co-amoxiclav was associated with longer pregnancy and neonatal necrotising enterocolitis. It was found out that there were no...

  • Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial.  // Critical Care;2012, Vol. 16 Issue 1, pR28 

    The article presents a study that investigated the effects of early use of broad-spectrum antimicrobials in critically ill patients with hospital-acquired pneumonia (HAP). In the study, between November 2004 and October 2006, 109 MICU patients with HAP were enrolled. Initial antimicrobial...

  • Research brief: Antibiotic regimens in COPD.  // GP: General Practitioner;12/3/2004, p6 

    The article discusses a research report on antibiotics. A week's course of levofloxacin is as clinically effective as a 10-day course of clarithromycin for people with COPD exacerbation, a German study of 511 patients has shown. A higher bacteriological eradication rate was achieved with...

  • Antimicrobial drugs for persistent diarrhoea of unknown or non-specific cause in children under six in low and middle income countries: systematic review of randomized controlled trials. Abba, Katharine; Sinfield, Rebecca; Hart, C. Anthony; Garner, Paul // BMC Infectious Diseases;2009, Vol. 9 Issue 1, Special section p1 

    Background: A high proportion of children with persistent diarrhoea in middle and low income countries die. The best treatment is not clear. We conducted a systematic review to evaluate the effectiveness of antimicrobial drug treatment for persistent diarrhoea of unknown or non-specific cause....

  • Update on the Preventive Antibiotics in Stroke Study (PASS): a randomised controlled phase 3 clinical trial. Westendorp, Willeke F.; Vermeij, Jan-Dirk; van Geloven, Nan; Dippel, Diederik W. J.; Dijkgraaf, Marcel G. W.; van der Poll, Tom; Spanjaard, Lodewijk; Vermeij, Frederique H.; Nederkoorn, Paul J.; van de Beek, Diederik // Trials;2014, Vol. 15 Issue 1, p1 

    Background Stroke is a leading cause of death worldwide. Infections after stroke occur in 30% of stroke patients and are strongly associated with unfavourable outcome. Preventive antibiotic therapy lowers infection rate in patients after stroke, however, the effect of preventive antibiotic...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics